CISPLATIN AS 1ST-LINE THERAPY FOR METASTATIC BREAST-CANCER
CISPLATIN AS 1ST-LINE THERAPY FOR METASTATIC BREAST-CANCER
复制标题
DOI：
10.1200/jco.1988.6.12.1811
复制
发表时间：
1988-12-01
影响因子：
45.3
通讯作者：
EINHORN, LH
中科院分区：
文献类型：
--
作者：
SLEDGE, GW;LOEHRER, PJ;EINHORN, LH
顺铂用作转移性乳腺癌 (MBC) 的二线和三线化疗时仅具有很小的活性。美国尚无评估顺铂治疗未接受化疗的 MBC 患者的 I 期研究。因此，我们连续用顺铂 30 mg/m2/d 治疗 20 名患者，每 3 周治疗 4 天，最多 6 个疗程。我们在 19 名可评估患者中的 9 名（47%）中获得了部分缓解，其中肝脏、肺和软组织指标病变均有缓解。我们的数据表明，顺铂作为 MBC 的一线治疗具有显着的单药活性，应考虑纳入一线联合化疗方案。
Cisplatin has had only minimal activity when used as second- and third-line chemotherapy for metastatic breast cancer (MBC). There have been no phase I studies in the United States evaluating cisplatin in patients with MBC with no prior chemotherapy. We therefore treated 20 consecutive patients with cisplatin 30 mg/m2/d for four days every 3 weeks for a maximum of six courses. We obtained partial responses in nine of 19 evaluable patients (47%), with responses in liver, lung, and soft tissue indicator lesions. Our data suggest that cisplatin has substantial single-agent activity as front-line therapy in MBC, and should be considered for inclusion in first-line combination chemotherapy regimens.